Sept. 4, 2025 — Sentec recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its LuMon Electrical Impedance Tomography (EIT) system for premature infant, infant, adolescent and adult patients — making it the first EIT technology in the United States available for premature infants and for spontaneously breathing patients. While the LuMon System can be used to monitor a variety of patients, whether ventilated or spontaneously breathing, the premature infants and other patients in the NICU may stand to benefit the most from EIT's insights at the bedside. That visualization helps us better understand each patient's respiratory condition and determine the strategies we need to employ for their specific needs." With the first-ever FDA clearance for premature infants and soft, fabric belts small enough for even very low birthweight infants, the LuMon™ System is positioned to help clinicians deliver gentle and effective respiratory care for the uniquely fragile and complex patients in the NICU. While the basis of electrical impedance tomography and its use for imaging regional lung function has been present in research for many years, the LuMon™ system is first EIT technology available for routine clinical bedside use with premature infants in the United States, and can impact patient care and clinical decision making today.